Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 30,616 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 30,616 shares of the company’s stock in a transaction that occurred on Wednesday, January 14th. The shares were sold at an average price of $0.57, for a total transaction of $17,451.12. Following the sale, the director directly owned 2,236,055 shares of the company’s stock, valued at approximately $1,274,551.35. This represents a 1.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Thursday, January 15th, Luke Evnin sold 37,413 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.55, for a total value of $20,577.15.
• On Tuesday, January 13th, Luke Evnin sold 43,198 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.55, for a total transaction of $23,758.90.
• On Monday, January 12th, Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.57, for a total value of $33,618.60.
• On Friday, January 9th, Luke Evnin sold 24,678 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total transaction of $15,053.58.
• On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $4,861.08.
• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total transaction of $26,494.65.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.62, for a total value of $15,476.44.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock opened at $0.55 on Friday. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The stock’s fifty day moving average is $0.84 and its two-hundred day moving average is $1.23. Werewolf Therapeutics, Inc. has a 52 week low of $0.53 and a 52 week high of $2.38. The company has a market capitalization of $26.74 million, a PE ratio of -0.34 and a beta of 0.77.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. As a group, analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quadrature Capital Ltd purchased a new position in shares of Werewolf Therapeutics during the 2nd quarter valued at about $28,000. Qube Research & Technologies Ltd acquired a new stake in Werewolf Therapeutics during the second quarter worth about $48,000. AQR Capital Management LLC acquired a new stake in Werewolf Therapeutics during the first quarter worth about $79,000. Y Intercept Hong Kong Ltd purchased a new position in Werewolf Therapeutics during the second quarter valued at approximately $92,000. Finally, Bridgeway Capital Management LLC lifted its holdings in Werewolf Therapeutics by 157.7% in the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after acquiring an additional 62,414 shares during the period. 64.84% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Citigroup lowered Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, December 19th. Bank of America dropped their target price on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. HC Wainwright lowered their price objective on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Finally, Wedbush lowered Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 target price for the company. in a research note on Friday, December 19th. Three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Werewolf Therapeutics has a consensus rating of “Hold” and an average target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.